A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.

Br J Cancer · 2013 · PMC3790192 · PMID 24022191

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

did not reach statistical significanceP =0.063so close (0.05 < p ≤ 0.1)

Exposure values of imatinib and CGP74588 on C1D1 (AUC 0-inf ) and C2D1 (AUC 0–24 h because imatinib is at steady state) appeared to increase, but these effects did not reach statistical significance ( P =0.063), as shown in Figures 2A and B and Table 4 .

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.